Not much evidence is available and published on this topic, but patients with a 5q chromosomal abnormality seem to respond with a significantly lower response rate to both the EPO alfa and darbepoetin isoforms (with or without G-CSF) than MDS patients without a 5q deletion 27. Here, CSF3 is linked to myelodysplastic syndrome.